Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Oral time-limited duvelisib/venetoclax in R/R CLL

Matthew Davids • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Duvelisib Venetoclax

Matthew Davids, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the phase I trial (NCT03534323) assessing duvelisib in combination with venetoclax as a possible treatment for patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL). Early efficacy data for this 1-year time-limited, all oral regimen are promising. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Matthew Davids

Richter’s transformation: biology & ongoing trials in the field
Carsten Niemann et al. • 25 Mar 2024
1:53
CLL highlights from ASH 2023: the FLAIR study
Matthew Davids • 9 Dec 2023
2:15
CDK9 inhibition with voruciclib for treating AML and R/R B-cell NHL
Matthew Davids • 9 Dec 2023
1:21
Clinical characteristics and outcomes of the double refractory CLL/SLL patient population
Matthew Davids • 9 Dec 2023

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals